Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease

This is the first in human treatment with ST-920, a recombinant AAV2/6 vector encoding the cDNA for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels …

anhidrosis
lyso-gb3
acroparesthesia
cornea verticillata
gene therapy
  • 114 views
  • 29 Apr, 2022
  • 12 locations
Study of the Effects of Fabrazyme Treatment on Lactation and Infants

The study will last for up to 2 years (24 months). Full participation for both mother and infant is 24 months, full participation of mother and development of infant is 24 months, while full participation of mother and no infant participation is 6 months

fabrazyme
agalsidase beta
  • 75 views
  • 13 May, 2022
  • 2 locations
Study of the Effects of Fabrazyme Treatment on Lactation and Infants

The study will last for up to 2 years (24 months). Full participation for both mother and infant is 24 months, full participation of mother and development of infant is 24 months, while full participation of mother and no infant participation is 6 months

fabrazyme
agalsidase beta
  • 0 views
  • 13 May, 2022
  • 2 locations
Canadian Fabry Disease Initiative (CFDI) National Registry (CFDI-NR)

CFDI NATIONAL REGISTRY Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes

deficiency
genetic disorder
deficit
neuropathic pain
alpha-galactosidase
  • 149 views
  • 23 Jan, 2022
  • 5 locations
Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study

The investigators will perform a study with two major components. The first is a natural history study of untreated Fabry patients. This study component will detail kidney microscopic structural changes in Fabry patients before starting enzyme replacement therapy and will correlate these changes with kidney function, including glomerular filtration rate …

renal function
replacement therapy
  • 43 views
  • 16 Sep, 2021
  • 2 locations